Media stories about NuVasive (NASDAQ:NUVA) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.6969846748253 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
NuVasive (NASDAQ:NUVA) opened at 50.82 on Monday. NuVasive has a 1-year low of $49.25 and a 1-year high of $81.68. The stock has a market cap of $2.58 billion, a PE ratio of 80.03 and a beta of 1.04. The firm’s 50-day moving average price is $57.00 and its 200 day moving average price is $69.32.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. NuVasive’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share. Equities research analysts expect that NuVasive will post $1.99 EPS for the current year.
Several equities research analysts have commented on NUVA shares. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price target (up from $85.00) on shares of NuVasive in a research report on Wednesday, June 28th. Robert W. Baird cut shares of NuVasive from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $79.00 to $72.00 in a research report on Friday, July 28th. Gabelli reiterated a “buy” rating on shares of NuVasive in a research report on Monday, July 31st. Royal Bank Of Canada reiterated a “buy” rating and issued a $85.00 price target on shares of NuVasive in a research report on Thursday, July 20th. Finally, Zacks Investment Research cut shares of NuVasive from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $76.62.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/16/nuvasive-nuva-earning-somewhat-favorable-press-coverage-analysis-finds.html.
In other NuVasive news, CEO Gregory T. Lucier purchased 2,000 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were bought at an average price of $61.52 per share, with a total value of $123,040.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Peter Michael Leddy purchased 7,850 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average cost of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 14,850 shares of company stock worth $955,598. 1.20% of the stock is currently owned by insiders.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.